SEARCH WITHIN CONTENT
Citation Information : Journal of Epileptology. Volume 24, Issue 2, Pages 87-94, DOI: https://doi.org/10.1515/joepi-2016-0016
License : (CC BY 4.0)
Received Date : 10-November-2016 / Accepted: 19-December-2016 / Published Online: 22-December-2016
Open Access article funded by This study was supported by an unrestricted research grant from GlaxoSmithKline (Brentford, UK). The
Introduction. Patients with pharmacoresistant epilepsy are usually treated with two or more antiepileptic drugs (AEDs). The search for therapeutically efficacious AED combinations is still a challenging issue for clinicians and epileptologists throughout the world.
Aim. To determine the interaction profile for the combination of retigabine (RTG) and oxcarbazepine (OXC) in both, the model of tonic-clonic seizures, the maximal electroshock (MES)-induced seizure model and chimney test (motor performance) in adult male albino Swiss mice.
Methods. Isobolographic analysis (type I) was applied to characterize interactions for the combination of RTG with OXC with respect to its anticonvulsant and acute side (neurotoxic) effects, as determined in the MES and chimney tests, respectively.
Results. The combination of RTG with OXC at the fixed-ratios of 1:3, 1:1 and 3:1 produced additive interactions in the MES test in mice. Similarly, the combination of RTG with OXC at the fixed-ratio of 1:1 produced additive interaction with a tendency towards sub-additivity in the chimney test in mice. Measurement of total brain concentrations of both AEDs revealed that RTG did not affect total brain concentrations of OXC and inversely, OXC had no impact on RTG’s total brain concentrations, confirming pharmacodynamic interaction between the drugs.
Conclusions. The additive pharmacodynamic interactions in both the MES and chimney tests in mice were observed for the combination of RTG with OXC.
Berenbaum M.C.: What is synergy? Pharmacological Reviews, 1989, 41: 93–141.
Boissier J.R., Tardy J., Diverres J.C.: Une nouvelle méthode simple pour explorer l’action «tranquillisante»: le test de la cheminée. Pharmacology, 1960, 3: 81–84.
Brodie M.J., Sills G.J.: Combining antiepileptic drugs-rational polytherapy? Seizure, 2011, 20: 369–375.
Czapiński P., Błaszczyk B., Czuczwar S.J.: Mechanisms of action of antiepileptic drugs. Current Topics in Medical Chemistry, 2005, 5: 3–14.
Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H. et al.: Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 2000, 41: 1364–1374.
European Medicines Agency: Trobalt: EPAR – Product Information. 2016 (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001245/human_med_001431.jsp&mid=WC0b01ac058001d124) [accessed 08 NOV 2016].
Gessner P.K.: Isobolographic analysis of interactions: an update on applications and utility. Toxicology, 1995, 105: 161–179.
Kondrat-Wróbel M.W., Łuszczki J.J.: Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model – an isobolographic analysis. Health Problems of Civilization, 2016, 10: 55–61.
Kwan P., Brodie M.J.: Combination therapy in epilepsy: when and what to use. Drugs, 2006, 66: 1817–1829.
Kwan P., Schachter S.C., Brodie M.J.: Drug-resistant epilepsy. The New England Journal of Medicine, 2011, 365: 919–926.
Lerche H., Daniluk J., Lotay N., DeRossett S., Edwards S., Brandt C.: Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. Seizure, 2015, 30: 93–100.
Litchfield J.T. Jr., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics, 1949, 96: 99–113.
Löscher W., Fassbender C.P., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Research, 1991, 8: 79–94.
Löscher W., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Research, 1991, 9: 1–10.
Łuszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Ratnaraj N., Patsalos P.N. et al.: Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia, 2006, 47: 10–20.
Łuszczki J.J., Andres M.M., Czuczwar S.J.: Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model-an isobolographic analysis. European Journal of Pharmacology, 2005a, 515: 54–61.
Łuszczki J.J., Antkiewicz-Michaluk L., Raszewski G., Czuczwar S.J.: Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Research, 2010a, 89: 207–219.
Łuszczki J.J., Borowicz K.K., Świąder M., Czuczwar S.J.: Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia, 2003, 44: 489–499.
Łuszczki J.J., Czuczwar S.J.: Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics – a comparative study. Epilepsy Research, 2003, 56: 27–42.
Łuszczki J.J., Czuczwar S.J.: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia, 2004, 45: 895–907.
Łuszczki J.J., Czuczwar, S.J.: Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. European Neuropsychopharmacology, 2005, 15: 133–142.
Łuszczki J.J., Filip D., Czuczwar S.J.: Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Research, 2010b, 91: 166–175.
Łuszczki J.J., Ratnaraj N., Patsalos P.N., Czuczwar S.J.: Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia, 2005b, 46: 344–355.
Łuszczki J.J., Wu J.Z., Raszewski G., Czuczwar S.J.: Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Archives of Pharmacology, 2009, 379: 163–179.
Łuszczki J.J., Zagaja M., Miziak B., Florek-Łuszczki M., Czuczwar S.J.: Synergistic interaction of retigabine with levetiracetam in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. Pharmacology, 2015, 96: 11–15.
Łuszczki J.J.: Interaction of pregabalin with carbamazepine in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Advances in Medical Sciences, 2010, 55: 43–52.
Łuszczki J.J.: Isobolographic analysis of interaction for threedrug combination of carbamazepine, phenobarbital and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology, 2016, 97: 259–264.
Perucca E.: Clinically relevant drug interactions with antiepileptic drugs. British Journal of Clinical Pharmacology, 2006, 61: 246–255.
Perucca E.: Pharmacological principles as a basis for polytherapy. Acta Neurologica Scandinavica, Suppl., 1995, 162: 31–34.
Rejdak K., Łuszczki J.J., Błaszczyk B., Chwedorowicz R., Czuczwar S.J.: Clinical utility of adjunctive retigabine in partial onset seizures in adults. Therapeutics and Clinical Risk Management, 2012, 8: 7–14.
Rundfeldt C., Netzer R.: Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung, 2000, 50: 1063–1070.
Tallarida R.J.: Quantitative methods for assessing drug synergism. Genes Cancer, 2011, 2: 1003–1008.
Tallarida R.J.: Revisiting the isobole and related quantitative methods for assessing drug synergism. Journal of Pharmacology and Experimental Therapeutics, 2012, 342: 2–8.
Tompson D.J., Crean C.S.: The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Current Clinical Pharmacology, 2014, 9: 148–156.
Treven M., Koenig X., Assadpour E., Gantumur E., Meyer C., Hilber K. et al.: The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia, 2015, 56: 647–657.
Żółkowska D., Zagaja M., Miziak B., Kondrat-Wróbel M.W., Załuska K., Florek-Łuszczki M. et al.: Isobolographic assessment of interactions between retigabine and phenytoin in the mouse maximal electroshock-induced seizure model and chimney test. Health Problems of Civilization, 2016, 10: 54–59.